Jinze Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jinze Li has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Qiang Wei
Department of Urology, Institute of Urology, West China Hospital of Sichuan University, Chengdu, Sichuan, China
3 shared publications - Bo Tang
Department of Urology, West China Hospital of Sichuan University, No. 37, Guoxue Lane, Chengdu 610041, China
2 shared publications - Daqing Tan
Department of Urology, West China Hospital of Sichuan University, No. 37, Guoxue Lane, Chengdu 610041, China
2 shared publications - Jinjiang Jiang
Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
2 shared publications Bailong Jiang
Department of Urology, Hospital of Chengdu University of Traditional Chinese Medicine
1 shared publication- Bo Chen
Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
1 shared publication
Latest Publications
- Open Access
- 25 August 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1874552
Resveratrol in benign prostatic hyperplasia: mechanistic insights and therapeutic perspectives
Benign prostatic hyperplasia (BPH) is a common age-related disorder characterized by progressive prostatic enlargement and lower urinary tract symptoms, yet current medical therapies remain constrained by delayed onset, incomplete efficacy, and treatment-related adverse effects. Resveratrol (Res), a naturally occurring polyphenol, has emerged as a promising candidate for BPH intervention because its pharmacological profile aligns closely with the multifactorial biology of the disease. This review synthesizes current evidence showing that Res may counteract BPH progression through coordinated regulation of several interconnected processes, including abnormal prostate cell proliferation, apoptosis resistance, oxidative stress, chronic inflammation, fibrotic remodeling, and androgen-related signaling. Rather than acting on a single target, Res appears to reshape the pro-hyperplastic microenvironment at multiple levels, providing a mechanistic rationale for its therapeutic potential. However, the available evidence remains predominantly preclinical, and its clinical translation is still limited by poor oral bioavailability, extensive first-pass metabolism, uncertainty regarding the active molecular species in prostate tissue, and the lack of standardized formulations and robust clinical trials. Overall, Res represents a biologically plausible but not yet clinically established strategy for BPH management.
- 25 August 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1874552
Open AccessResveratrol in benign prostatic hyperplasia: mechanistic insights and therapeutic perspectives
Benign prostatic hyperplasia (BPH) is a common age-related disorder characterized by progressive prostatic enlargement and lower urinary tract symptoms, yet current medical therapies remain constrained by delayed onset, incomplete efficacy, and treatment-related adverse effects. Resveratrol (Res), a naturally occurring polyphenol, has emerged as a promising candidate for BPH intervention because its pharmacological profile aligns closely with the multifactorial biology of the disease. This review synthesizes current evidence showing that Res may counteract BPH progression through coordinated regulation of several interconnected processes, including abnormal prostate cell proliferation, apoptosis resistance, oxidative stress, chronic inflammation, fibrotic remodeling, and androgen-related signaling. Rather than acting on a single target, Res appears to reshape the pro-hyperplastic microenvironment at multiple levels, providing a mechanistic rationale for its therapeutic potential. However, the available evidence remains predominantly preclinical, and its clinical translation is still limited by poor oral bioavailability, extensive first-pass metabolism, uncertainty regarding the active molecular species in prostate tissue, and the lack of standardized formulations and robust clinical trials. Overall, Res represents a biologically plausible but not yet clinically established strategy for BPH management.
- Open Access
- 21 April 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1799399
Development and explainability of a machine learning prediction model for histological prostatic inflammation in surgically treated patients with benign prostatic hyperplasia: a single-center internal validation study
Background: Histological prostatitis is highly prevalent among patients with benign prostatic hyperplasia (BPH) and has been shown to be closely associated with disease progression and postoperative outcomes. However, its diagnosis still mainly relies on postoperative or biopsy pathology, and there is a lack of non-invasive tools to estimate the risk of histological inflammation before surgery or biopsy. Methods: This was a single-center retrospective machine-learning prediction model study with internal validation, involving 723 patients admitted to the urology department of a tertiary medical center for BPH between June 2020 and June 2023. The cohort was randomly divided into a training set and a validation set in a 7:3 ratio. Least absolute shrinkage and selection operator (LASSO) regression and the Boruta algorithm were used for feature selection, on the basis of which six machine learning models were constructed. Model performance and clinical net benefit were evaluated using the area under the receiver operating characteristic curve, calibration, and decision curve analysis. Shapley additive explanations (SHAP) were applied to provide interpretability at both the global and individual levels, and the best-performing model was further deployed as an online prediction tool. Results: Among the 723 patients, 387 (53.5%) had histological prostatitis. Of the six machine learning models, the artificial neural network (ANN) model showed the best discriminative ability, with an AUC of 0.852 [95% confidence interval (CI): 0.804–0.899] in the validation set, overall performance superior to the other models, and the lowest Brier score (0.160). It also provided the greatest net benefit across a wide range of threshold probabilities. SHAP analysis indicated that prostate volume (PV), neutrophil-to-lymphocyte ratio (NLR), International Prostate Symptom Score (IPSS), age, systemic immune–inflammation index (SII), and acute urinary retention (AUR) were the key predictors driving model performance; higher values of these variables (or the presence of AUR) were associated with an increased predicted risk of histological prostatitis Conclusions: Machine learning models, particularly the ANN model, showed good discriminative ability and reasonable calibration for predicting the risk of histological prostatic inflammation. Age, prostate volume, IPSS score, AUR, NLR, and SII were identified as the most important predictors. This prediction model enables accurate and interpretable risk assessment of histological prostatitis in patients with BPH, thereby facilitating early identification of high-risk individuals, supporting refined risk stratification, and optimizing perioperative decision-making.
- 21 April 2026
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 13, 1799399
Open AccessDevelopment and explainability of a machine learning prediction model for histological prostatic inflammation in surgically treated patients with benign prostatic hyperplasia: a single-center internal validation study
Background: Histological prostatitis is highly prevalent among patients with benign prostatic hyperplasia (BPH) and has been shown to be closely associated with disease progression and postoperative outcomes. However, its diagnosis still mainly relies on postoperative or biopsy pathology, and there is a lack of non-invasive tools to estimate the risk of histological inflammation before surgery or biopsy. Methods: This was a single-center retrospective machine-learning prediction model study with internal validation, involving 723 patients admitted to the urology department of a tertiary medical center for BPH between June 2020 and June 2023. The cohort was randomly divided into a training set and a validation set in a 7:3 ratio. Least absolute shrinkage and selection operator (LASSO) regression and the Boruta algorithm were used for feature selection, on the basis of which six machine learning models were constructed. Model performance and clinical net benefit were evaluated using the area under the receiver operating characteristic curve, calibration, and decision curve analysis. Shapley additive explanations (SHAP) were applied to provide interpretability at both the global and individual levels, and the best-performing model was further deployed as an online prediction tool. Results: Among the 723 patients, 387 (53.5%) had histological prostatitis. Of the six machine learning models, the artificial neural network (ANN) model showed the best discriminative ability, with an AUC of 0.852 [95% confidence interval (CI): 0.804–0.899] in the validation set, overall performance superior to the other models, and the lowest Brier score (0.160). It also provided the greatest net benefit across a wide range of threshold probabilities. SHAP analysis indicated that prostate volume (PV), neutrophil-to-lymphocyte ratio (NLR), International Prostate Symptom Score (IPSS), age, systemic immune–inflammation index (SII), and acute urinary retention (AUR) were the key predictors driving model performance; higher values of these variables (or the presence of AUR) were associated with an increased predicted risk of histological prostatitis Conclusions: Machine learning models, particularly the ANN model, showed good discriminative ability and reasonable calibration for predicting the risk of histological prostatic inflammation. Age, prostate volume, IPSS score, AUR, NLR, and SII were identified as the most important predictors. This prediction model enables accurate and interpretable risk assessment of histological prostatitis in patients with BPH, thereby facilitating early identification of high-risk individuals, supporting refined risk stratification, and optimizing perioperative decision-making.
- Open Access
- 18 December 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1483855
Prognostic significance of hemoglobin, albumin, lymphocyte and platelet score in solid tumors: a pooled study
Objective: The high hemoglobin, albumin, lymphocyte, and platelet (HALP) score has been reported to be a good prognostic indicator for several malignancies. However, more evidence is needed before it can be introduced into clinical practice. Here, we systematically evaluated the predictive value of HALP for survival outcomes in patients with solid tumors. Methods: This study was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Assessing the Methodological Quality of Systematic Reviews (AMSTAR) Guidelines. In March 2024, an electronic literature search was performed for articles regarding the prognostic role of HALP in solid tumors. Data from studies with reported risk ratios (HRs) and 95% confidence intervals (CIs) were pooled in a meta-analysis. Study bias was assessed using the QUIPS tool. Results: Of the 729 articles reviewed, 45 cohorts including data from 17,049 patients with cancer were included in the pooled analysis. The pooled results demonstrated that elevated HALP score was significantly associated with favorable overall survival (HR = 0.60, 95% CI 0.54-0.67, p < 0.01), cancer-specific survival (HR = 0.53, 95% CI 0.44- 0.64, p < 0.01), progression-free survival (HR = 0.62, 95% CI 0.54-0.72, p < 0.01), recurrence-free survival (HR = 0.48, 95% CI 0.30-0.77, p < 0.01), and disease-free survival (HR = 0.72, 95% CI 0.57-0.82, p < 0.01). Subgroup analyses based on various confounding factors further revealed the consistent prognostic impact of HALP on overall survival in patients with solid tumors. Conclusions: Our findings suggest that high HALP is associated with better survival outcomes in patients. The HALP score is a potential prognostic biomarker in solid tumors, but it needs to be further studied whether it can improve the established prognostic model.
- 18 December 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1483855
Open AccessPrognostic significance of hemoglobin, albumin, lymphocyte and platelet score in solid tumors: a pooled study
Objective: The high hemoglobin, albumin, lymphocyte, and platelet (HALP) score has been reported to be a good prognostic indicator for several malignancies. However, more evidence is needed before it can be introduced into clinical practice. Here, we systematically evaluated the predictive value of HALP for survival outcomes in patients with solid tumors. Methods: This study was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and Assessing the Methodological Quality of Systematic Reviews (AMSTAR) Guidelines. In March 2024, an electronic literature search was performed for articles regarding the prognostic role of HALP in solid tumors. Data from studies with reported risk ratios (HRs) and 95% confidence intervals (CIs) were pooled in a meta-analysis. Study bias was assessed using the QUIPS tool. Results: Of the 729 articles reviewed, 45 cohorts including data from 17,049 patients with cancer were included in the pooled analysis. The pooled results demonstrated that elevated HALP score was significantly associated with favorable overall survival (HR = 0.60, 95% CI 0.54-0.67, p < 0.01), cancer-specific survival (HR = 0.53, 95% CI 0.44- 0.64, p < 0.01), progression-free survival (HR = 0.62, 95% CI 0.54-0.72, p < 0.01), recurrence-free survival (HR = 0.48, 95% CI 0.30-0.77, p < 0.01), and disease-free survival (HR = 0.72, 95% CI 0.57-0.82, p < 0.01). Subgroup analyses based on various confounding factors further revealed the consistent prognostic impact of HALP on overall survival in patients with solid tumors. Conclusions: Our findings suggest that high HALP is associated with better survival outcomes in patients. The HALP score is a potential prognostic biomarker in solid tumors, but it needs to be further studied whether it can improve the established prognostic model.
- Open Access
The Impact of Nutrient Supply on Prostate Cancer Risk Worldwide
We aim to explore the association between nutrient supply and the incidence of prostate cancer globally. We utilized national nutrient supply data from the Food and Agriculture Organization of the United Nations for 150 countries, including the average supply of total protein (APS), animal protein (AAPS), fat (AFS), animal protein/total protein ratio (ATR), and share of dietary energy supply derived from cereals, roots, and tubers (CR). Prostate cancer incidence data were sourced from the Global Burden Disease 2019 (GBD2019). Correlation, regression analyses, and subgroup analysis were conducted. Our findings imply that incidence of prostate cancer is significantly correlated to APS (ρ = 0.394, p < 0.01), AAPS (ρ = 0.560, p < 0.01), AFS (ρ = 0.522, p < 0.01), ATR (ρ = 0.592, p < 0.01), and CR (ρ = −0.667, p < 0.01). After adjusting for confounders, regression analysis showed linear relationships between the AAPS (β = 0.605, p = 0.006), ATR (β = 70.76, p = 0.005), CR (β = −1.4451, p < 0.01), and age-standardized incidence rates (ASIRs) of prostate cancer, while no association was observed with APS (β = 0.030, p = 0.483) or AFS (β = 0.237, p = 0.405). Subgroup analysis suggested that dietary supply indicators were associated with ASIR in middle, middle-high, and high SDI, but not in countries with low and middle-low SDI. In summary, prostate cancer rates globally correlate significantly with AAPS, ATR, and CR, but not with APS and AFS. When considering the SDI of countries, the relationship is generally more pronounced in economically advanced nations, but not evident in low and middle-low SDI countries.
Open AccessThe Impact of Nutrient Supply on Prostate Cancer Risk Worldwide
We aim to explore the association between nutrient supply and the incidence of prostate cancer globally. We utilized national nutrient supply data from the Food and Agriculture Organization of the United Nations for 150 countries, including the average supply of total protein (APS), animal protein (AAPS), fat (AFS), animal protein/total protein ratio (ATR), and share of dietary energy supply derived from cereals, roots, and tubers (CR). Prostate cancer incidence data were sourced from the Global Burden Disease 2019 (GBD2019). Correlation, regression analyses, and subgroup analysis were conducted. Our findings imply that incidence of prostate cancer is significantly correlated to APS (ρ = 0.394, p < 0.01), AAPS (ρ = 0.560, p < 0.01), AFS (ρ = 0.522, p < 0.01), ATR (ρ = 0.592, p < 0.01), and CR (ρ = −0.667, p < 0.01). After adjusting for confounders, regression analysis showed linear relationships between the AAPS (β = 0.605, p = 0.006), ATR (β = 70.76, p = 0.005), CR (β = −1.4451, p < 0.01), and age-standardized incidence rates (ASIRs) of prostate cancer, while no association was observed with APS (β = 0.030, p = 0.483) or AFS (β = 0.237, p = 0.405). Subgroup analysis suggested that dietary supply indicators were associated with ASIR in middle, middle-high, and high SDI, but not in countries with low and middle-low SDI. In summary, prostate cancer rates globally correlate significantly with AAPS, ATR, and CR, but not with APS and AFS. When considering the SDI of countries, the relationship is generally more pronounced in economically advanced nations, but not evident in low and middle-low SDI countries.
- Open Access
- 28 March 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (4) , 982-994
The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis
Background: The role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) remains controversial. In addition, several unanswered questions regarding the use of CN remain: Can CN provide survival benefits for patients with mRCC? Where do we place CN in the treatment sequence paradigm among patients with mRCC? How do we best stratify patients with mRCC for CN therapy? Materials and Methods: A search strategy was conducted in the PubMed, Embase, and Web of Science databases. Studies were included only in the English language. The risk of bias assessment was made by using ROBINS-I (Risk of Bias in Nonrandomized Studies of Interventions) and RoB 2 (Risk of Bias 2) tools. The expected outcomes were analyzed by meta-analyses with the fixed-effects model or random effects model, including overall survival (OS) and progression-free survival (PFS). The measure of effect was the hazard ratio (HR) with a 95% CI, and sensitivity analysis was conducted to assess the reliability of the final results. Results: A total of 30 studies were included in the qualitative analysis. The HR for OS was 0.55 (95% CI, 0.50–0.61), and PFS was 0.72 (95% CI, 0.66–0.80), favoring CN compared with no CN. The upfront CN plus targeted therapy (TT) group had superior OS (HR, 0.57; 95% CI, 0.51–0.64) compared with the TT alone group. Furthermore, upfront CN plus systemic therapy (ST) was associated with numerically inferior OS compared with ST plus deferred CN in patients with mRCC (HR, 1.31; 95% CI, 0.98–1.74). Finally, the leave-one-out test of sensitivity analysis indicated that the results of this meta-analysis were stable and reliable in the overall HR estimates for these survival outcomes. Conclusions: First, CN was associated with better survival than no CN in patients with mRCC. Second, the combination of upfront CN and TT may lead to superior survival outcomes compared to TT alone in patients with mRCC. Survival outcomes were similar between the upfront CN+ST group and the ST+deferred CN group in patients with mRCC. Exact patient selection based on baseline prognostic factors is needed to promise maximal survival for patients with mRCC.
- 28 March 2023
- Published by Wolters Kluwer Health in International Journal of Surgery
- Vol. 109 (4) , 982-994
Open AccessThe role of cytoreductive nephrectomy in metastatic renal cell carcinoma in the targeted therapy and immunological therapy era: a systematic review and meta-analysis
Background: The role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC) remains controversial. In addition, several unanswered questions regarding the use of CN remain: Can CN provide survival benefits for patients with mRCC? Where do we place CN in the treatment sequence paradigm among patients with mRCC? How do we best stratify patients with mRCC for CN therapy? Materials and Methods: A search strategy was conducted in the PubMed, Embase, and Web of Science databases. Studies were included only in the English language. The risk of bias assessment was made by using ROBINS-I (Risk of Bias in Nonrandomized Studies of Interventions) and RoB 2 (Risk of Bias 2) tools. The expected outcomes were analyzed by meta-analyses with the fixed-effects model or random effects model, including overall survival (OS) and progression-free survival (PFS). The measure of effect was the hazard ratio (HR) with a 95% CI, and sensitivity analysis was conducted to assess the reliability of the final results. Results: A total of 30 studies were included in the qualitative analysis. The HR for OS was 0.55 (95% CI, 0.50–0.61), and PFS was 0.72 (95% CI, 0.66–0.80), favoring CN compared with no CN. The upfront CN plus targeted therapy (TT) group had superior OS (HR, 0.57; 95% CI, 0.51–0.64) compared with the TT alone group. Furthermore, upfront CN plus systemic therapy (ST) was associated with numerically inferior OS compared with ST plus deferred CN in patients with mRCC (HR, 1.31; 95% CI, 0.98–1.74). Finally, the leave-one-out test of sensitivity analysis indicated that the results of this meta-analysis were stable and reliable in the overall HR estimates for these survival outcomes. Conclusions: First, CN was associated with better survival than no CN in patients with mRCC. Second, the combination of upfront CN and TT may lead to superior survival outcomes compared to TT alone in patients with mRCC. Survival outcomes were similar between the upfront CN+ST group and the ST+deferred CN group in patients with mRCC. Exact patient selection based on baseline prognostic factors is needed to promise maximal survival for patients with mRCC.
- Open Access
- 24 October 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (21) , 6261
Prognostic Utility of the Modified Glasgow Prognostic Score in Urothelial Carcinoma: Outcomes from a Pooled Analysis
Background: Many studies explored the prognostic value of the modified Glasgow Prognostic Score (mGPS) in urothelial carcinoma (UC), but the results are controversial. This study aimed to quantify the relationship between pretreatment mGPS and survival in patients with UC. Methods: A systematic literature search was conducted using Embase, PubMed, and Web of Science to identify eligible studies published before August 2022. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess the association between pretreatment mGPS and the prognosis of UC. Results: Thirteen eligible studies involving 12,524 patients were included. A high mGPS was significantly associated with poor overall survival (mGPS 1/0: HR = 1.33, 95% CI 1.12–1.58, p = 0.001; mGPS 2/0: HR = 2.02, 95% CI 1.43–2.84, p < 0.0001), progression-free survival (mGPS 1/0: HR = 1.26, 95% CI 1.03–1.53, p = 0.021; mGPS 2/0: HR = 1.76, 95% CI 1.12–2.77, p = 0.013), recurrence-free survival (mGPS 1/0: HR = 1.36, 95% CI 1.18–1.56, p < 0.0001; mGPS 2/0: HR = 1.70, 95% CI 1.44–2.000, p < 0.0001), and cancer-specific survival (mGPS 2/0: HR = 1.81, 95% CI 1.30–2.52, p < 0.0001). A subgroup analysis of OS also yielded similar results. Conclusions: Evidence suggests that high pretreatment mGPS in UC is closely related to poor survival. Pre-treatment mGPS is a powerful independent prognostic factor in patients with UC.
- 24 October 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (21) , 6261
Open AccessPrognostic Utility of the Modified Glasgow Prognostic Score in Urothelial Carcinoma: Outcomes from a Pooled Analysis
Background: Many studies explored the prognostic value of the modified Glasgow Prognostic Score (mGPS) in urothelial carcinoma (UC), but the results are controversial. This study aimed to quantify the relationship between pretreatment mGPS and survival in patients with UC. Methods: A systematic literature search was conducted using Embase, PubMed, and Web of Science to identify eligible studies published before August 2022. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) were used to assess the association between pretreatment mGPS and the prognosis of UC. Results: Thirteen eligible studies involving 12,524 patients were included. A high mGPS was significantly associated with poor overall survival (mGPS 1/0: HR = 1.33, 95% CI 1.12–1.58, p = 0.001; mGPS 2/0: HR = 2.02, 95% CI 1.43–2.84, p < 0.0001), progression-free survival (mGPS 1/0: HR = 1.26, 95% CI 1.03–1.53, p = 0.021; mGPS 2/0: HR = 1.76, 95% CI 1.12–2.77, p = 0.013), recurrence-free survival (mGPS 1/0: HR = 1.36, 95% CI 1.18–1.56, p < 0.0001; mGPS 2/0: HR = 1.70, 95% CI 1.44–2.000, p < 0.0001), and cancer-specific survival (mGPS 2/0: HR = 1.81, 95% CI 1.30–2.52, p < 0.0001). A subgroup analysis of OS also yielded similar results. Conclusions: Evidence suggests that high pretreatment mGPS in UC is closely related to poor survival. Pre-treatment mGPS is a powerful independent prognostic factor in patients with UC.